Dr. Scott Gottlieb on Trump's Executive Order for Lower Drug Prices

Executive Order on Drug Pricing

• 💡 The executive order is seen as a statement of policy intent to lower drug prices and align US prices with those in Europe.
• ⚠️ A key component discussed is drug importation, a scheme from the first Trump administration that had stringent provisions making it difficult to implement at scale due to concerns about counterfeit drugs.

Potential Policy Mechanisms

• 🎯 The administration might pursue policies through Medicare, such as implementing most-favored-nation pricing (European pricing) or a demonstration project through CMI.
• ⚖️ Past attempts, like the IPI, were struck down by courts, suggesting a more tailored approach might be necessary to pass judicial review.
• 🤝 An opportunity exists for pharmaceutical companies to negotiate with the administration on tiered global pricing, a policy from the early 2000s.

Drug Pricing Differentials and Subsidization

• 📊 While list prices for drugs are higher in the US than in Europe, actual prices after discounts can be lower, making the real price differentials less significant than they appear.
• 🌍 Adjusting prices for GDP per capita reduces or eliminates many differentials, indicating that products are priced based on market affordability.
• ⚠️ Many countries impose utilization restrictions in exchange for preferential pricing, which can limit access to drugs if companies do not offer favorable prices.

Impact on Biotech and Capital Formation

• 📉 The Inflation Reduction Act (IRA) and potential tariffs on drugs manufactured abroad are already mitigating capital formation for biotech companies.
• 🔬 A slowdown at the FDA and recent appointments hostile to cell and gene therapy approvals are also impacting the industry, particularly company valuations and cash flows.
• ⚠️ These combined pressures may lead to reduced R&D budgets as companies seek to offset losses.